Merrimack Pharmaceuticals Inc (OQ:MACK)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: One Broadway, 14Th Floor
CAMBRIDGE MA 02142
Tel: N/A
Website: https://www.merrimack.com
IR: See website
<
Key People
Gary L. Crocker
Chairman of the Board, President, Treasurer
   
Business Overview
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company's wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Financial Overview
For the fiscal year ended 31 December 2023, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss decreased 24% to $1.2M. Lower net loss reflects Interest income increase from $188K to $868K (income), General and administrative - Balancing v decrease of 5% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.11 to -$0.08.
Reporting Currency: U.S. Dollars
Enterprise value: $195.47M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$2.18M as of Dec 31, 2023
Net annual income (TTM): -$1.18M as of Dec 31, 2023
Free cash flow (TTM): -$1.52M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 14,531,760 as of Mar 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.